277 related articles for article (PubMed ID: 16995354)
1. [Start of insulin therapy. How to ensure patient compliance?].
MMW Fortschr Med; 2006 Aug; 148(35-36):12-3. PubMed ID: 16995354
[No Abstract] [Full Text] [Related]
2. [American Diabetes Association's Annual Meeting: new data on insulin glargine: early combination promises more success].
MMW Fortschr Med; 2005 Aug; 147(33-34):44-5. PubMed ID: 16138636
[No Abstract] [Full Text] [Related]
3. Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy.
Kazda C; Hülstrunk H; Helsberg K; Langer F; Forst T; Hanefeld M
J Diabetes Complications; 2006; 20(3):145-52. PubMed ID: 16632233
[TBL] [Abstract][Full Text] [Related]
4. Basal insulin glargine vs prandial insulin lispro in type 2 diabetes.
Roden M
Lancet; 2008 Aug; 372(9636):371; author reply 372. PubMed ID: 18675682
[No Abstract] [Full Text] [Related]
5. Insulin glargine clinical trials.
White JR
Clin Ther; 2004 Jul; 26(7):1179-81; discussion 1182-3. PubMed ID: 15336483
[No Abstract] [Full Text] [Related]
6. Initiation of insulin therapy in patients with type 2 diabetes failing oral therapy: response to Mikhail and Cope and to Janka.
Raskin P
Diabetes Care; 2005 Nov; 28(11):2811. PubMed ID: 16249569
[No Abstract] [Full Text] [Related]
7. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial.
Bretzel RG; Nuber U; Landgraf W; Owens DR; Bradley C; Linn T
Lancet; 2008 Mar; 371(9618):1073-84. PubMed ID: 18374840
[TBL] [Abstract][Full Text] [Related]
8. Basal insulin glargine vs prandial insulin lispro in type 2 diabetes.
Arnolds S; Rave K
Lancet; 2008 Aug; 372(9636):370-1; author reply 372. PubMed ID: 18675680
[No Abstract] [Full Text] [Related]
9. Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy.
Malone JK; Kerr LF; Campaigne BN; Sachson RA; Holcombe JH;
Clin Ther; 2004 Dec; 26(12):2034-44. PubMed ID: 15823767
[TBL] [Abstract][Full Text] [Related]
10. [Acute blood sugar peaks endanger blood vessels: the postprandial situation to be controlled better].
MMW Fortschr Med; 2006 Jun; 148(26):57. PubMed ID: 16875385
[No Abstract] [Full Text] [Related]
11. Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial.
Miser WF; Arakaki R; Jiang H; Scism-Bacon J; Anderson PW; Fahrbach JL
Clin Ther; 2010 May; 32(5):896-908. PubMed ID: 20685497
[TBL] [Abstract][Full Text] [Related]
12. Starting insulin therapy in type 2 diabetes: lesson 1.
McCall AL
Curr Diab Rep; 2005 Oct; 5(5):325-6. PubMed ID: 16188164
[No Abstract] [Full Text] [Related]
13. Ultra-long-acting insulins for a lifestyle-related pandemic.
Kudva YC; Basu A
Lancet; 2011 Mar; 377(9769):880-1. PubMed ID: 21396704
[No Abstract] [Full Text] [Related]
14. [New fast-acting insulin analog. This insulin profits type l and type 2 diabetics].
Wepner U
MMW Fortschr Med; 2004 Nov; 146(47):62-3. PubMed ID: 15624662
[No Abstract] [Full Text] [Related]
15. Insulin glargine in the treatment of type 1 and type 2 diabetes.
Barnett AH
Vasc Health Risk Manag; 2006; 2(1):59-67. PubMed ID: 17319470
[TBL] [Abstract][Full Text] [Related]
16. Insulin glargine and educational intervention in patients with type 2 diabetes in clinical practice: long-term improvement in glycaemic control without weight gain.
Schreiber SA; Russmann A
Exp Clin Endocrinol Diabetes; 2006 Jan; 114(1):41-2. PubMed ID: 16450317
[No Abstract] [Full Text] [Related]
17. Insulin therapy for type 2 diabetes: rescue, augmentation, and replacement of beta-cell function.
Mayfield JA; White RD
Am Fam Physician; 2004 Aug; 70(3):489-500. PubMed ID: 15317436
[TBL] [Abstract][Full Text] [Related]
18. Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro.
Rosenstock J; Fonseca VA; Gross JL; Ratner RE; Ahrén B; Chow FC; Yang F; Miller D; Johnson SL; Stewart MW; Leiter LA;
Diabetes Care; 2014 Aug; 37(8):2317-25. PubMed ID: 24898300
[TBL] [Abstract][Full Text] [Related]
19. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naïve patients with type 2 diabetes receiving oral antidiabetes agents.
Jacober SJ; Scism-Bacon JL; Zagar AJ
Diabetes Obes Metab; 2006 Jul; 8(4):448-55. PubMed ID: 16776752
[TBL] [Abstract][Full Text] [Related]
20. [New data on hypoglycemia risk and beta cell function].
MMW Fortschr Med; 2007 Nov; 149(44):57. PubMed ID: 18078171
[No Abstract] [Full Text] [Related]
[Next] [New Search]
